STOCK TITAN
  1. Home
  2. Sec-filings
  3. ANAB
  4. [Form 4] ANAPTYSBIO, INC Insider Trading Activity

AnaptysBio (ANAB) CMO reports RSU, option grants, sale of stock

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

AnaptysBio, Inc. Chief Medical Officer Paul F. Lizzul reported multiple equity transactions. On January 6, 2026, 6,145 restricted stock units (RSUs) converted into the same number of common shares for no cash cost, and his common stock holdings became 39,448 shares. That day he also received 21,400 new RSUs and a stock option for 29,000 shares.

The new RSUs vest 25% per year starting January 6, 2027, while the option vests 25% on January 6, 2027 and then monthly in equal installments, all contingent on continued service. On January 7, 2026, he sold 2,235 common shares at $45.11 solely to cover tax withholding from the RSU vesting, leaving 37,213 common shares owned directly.

Positive

  • None.

Negative

  • None.
Insider Lizzul Paul F.
Role Chief Medical Officer
Sold 2,235 shs ($101K)
Type Security Shares Price Value
Sale Common Stock 2,235 $45.11 $101K
Exercise Restricted Stock Unit 6,145 $0.00 --
Grant/Award Restricted Stock Unit 21,400 $0.00 --
Grant/Award Stock Option (right to buy) 29,000 $0.00 --
Exercise Common Stock 6,145 $0.00 --
Holdings After Transaction: Common Stock — 37,213 shares (Direct); Restricted Stock Unit — 6,145 shares (Direct); Stock Option (right to buy) — 29,000 shares (Direct)
Footnotes (1)
  1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The stock option vests as to 25% of the total shares on January 6, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lizzul Paul F.
(Last) (First) (Middle)
C/O ANAPTYSBIO, INC.
10770 WATERIDGE CIRCLE, SUITE 210
(Street)
SAN DIEGO CA 92121
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ANAPTYSBIO, INC [ ANAB ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Medical Officer
3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/06/2026 M 6,145 A (1) 39,448 D
Common Stock 01/07/2026 S(2) 2,235 D $45.11 37,213 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit (1) 01/06/2026 M 6,145 (3) (3) Common Stock 6,145 $0 6,145 D
Restricted Stock Unit (1) 01/06/2026 A 21,400 (4) (4) Common Stock 21,400 $0 21,400 D
Stock Option (right to buy) $43.91 01/06/2026 A 29,000 (5) 01/05/2036 Common Stock 29,000 $0 29,000 D
Explanation of Responses:
1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
2. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
3. The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
4. The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
5. The stock option vests as to 25% of the total shares on January 6, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
/s/ Eric Loumeau, Attorney-in-Fact 01/08/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did ANAB Chief Medical Officer Paul F. Lizzul report on this Form 4?

The Form 4 shows 6,145 RSUs converting into common stock on January 6, 2026, grants of 21,400 new RSUs and a 29,000-share stock option, plus a sale of 2,235 common shares at $45.11 on January 7, 2026 to cover taxes.

How many AnaptysBio (ANAB) shares does the CMO own after these transactions?

After the reported transactions, Paul F. Lizzul directly owns 37,213 shares of AnaptysBio common stock, as shown in the Form 4.

Were the AnaptysBio (ANAB) insider share sales discretionary or for tax withholding?

The Form 4 footnotes state the 2,235-share sale on January 7, 2026 was made to cover tax withholding obligations from RSU vesting and "does not represent a discretionary transaction" by the reporting person.

What are the vesting terms of the new AnaptysBio RSU grant to the CMO?

The 21,400 RSUs granted on January 6, 2026 vest 25% annually starting January 6, 2027 until fully vested, subject to Paul F. Lizzul continuing to provide service on each vesting date.

What are the vesting terms of the 29,000-share AnaptysBio stock option granted to the CMO?

The 29,000-share stock option granted on January 6, 2026 vests 25% on January 6, 2027, then vests as to 1/48 of the total shares monthly until fully vested, conditioned on continued service.

What does each AnaptysBio RSU reported in this Form 4 represent?

According to the footnotes, each restricted stock unit (RSU) represents a contingent right to receive one share of AnaptysBio common stock upon settlement for no consideration.